Shots:

• The company launched its new business division, Similis Bio to improve efficiency & costs for biosimilar development by using the combined experience & technical knowledge of leaders in analytical, cell-line & process development
• Similis will supply companies & offers analytical & process development data to determine an appropriate biosimilar target, accelerate early program development & reduce analytical costs
• Similis Bio will foster co-development agreements with companies to develop biosimilar programs in which partners will get an exclusive right to purchase multiple programs. JSR designed Similis’ collaboration model is intended to reduce the risks of canceled programs and extend market analysis timelines

Ref: Businesswire | Image: JSR Life Sciences